부산대학교 도서관

Ahmad S; Mahnashi MH; Alyami BA; Alqahtani YS; Ullah F; Ayaz M; Tariq M; Sadiq A; Rashid U

Drug Design, Development and Therapy, Vol Volume 15, Pp 1299-1313 (2021)

Khan NH; Ullah F; Khan TA; Zafar U; Farhan Ali Khan M; Mustaqeem M; Shah SS; Wu DD; Ji XY

Clinical, Cosmetic and Investigational Dermatology, Vol Volume 14, Pp 9-21 (2021)

Ahmad A; Ullah F; Sadiq A; Ayaz M; Saeed Jan M; Shahid M; Wadood A; Mahmood F; Rashid U; Ullah R; Sahibzada MUK; Alqahtani AS; Mahmood HM

Drug Design, Development and Therapy, Vol Volume 14, Pp 2165-2178 (2020)

Hussain S; Ullah F; Ayaz M; Ali Shah SA; Ali Shah AH; Shah SM; Wadood A; Aman W; Ullah R; Shahat AA; Nasr FA

Drug Design, Development and Therapy, Vol Volume 13, Pp 4195-4205 (2019)

Ahmad A; Ullah F; Sadiq A; Ayaz M; Rahim H; Rashid U; Ahmad S; Jan MS; Ullah R; Shahat AA; Mahmood HM

Drug Design, Development and Therapy, Vol Volume 13, Pp 4185-4194 (2019)

Shah SMH; Ullah F; Khan S; Shah SMM; Matas MD; Hussain Z; Minhas MU; AbdEl-Salam NM; Assi KH; Isreb M

Drug Design, Development and Therapy, Vol Volume 10, Pp 3837-3850 (2016)

Dima D; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Goel U; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.; Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Ibeh N; Department of Pathology and Laboratory Medicine, University of Texas, Houston, Texas, USA.; Ullah F; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.; Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Mazzoni S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Mehdi A; Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio, USA.; Rudoni J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Raza S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; De Simone N; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Williams L; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Khan A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Rashid A; Department of Internal Medicine, University of Kansas, Kansas City, Kansas, USA.; Rice M; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Ricci K; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Samaras C; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Valent J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Anderson LD; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Anwer F; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.; Khouri J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

Khan S; Department of Chemistry, Abbottabad University of Science and Technology (AUST), Abbottabad 22500, Pakistan. Electronic address: shoaibkhanswati@gmail.com.; Hussain R; Department of Chemistry, Hazara University, Mansehra 21120, Pakistan. Electronic address: rafaqathussain0347@gmail.com.; Khan Y; Department of Chemistry, COMSATS University Islamabad campus, Islamabad 45550, Pakistan.; Iqbal T; Department of Chemistry, Abbottabad University of Science and Technology (AUST), Abbottabad 22500, Pakistan.; Ullah F; Department of Chemistry, Abbottabad University of Science and Technology (AUST), Abbottabad 22500, Pakistan.; Felemban S; Department of Chemistry, Faculty of Applied Science, University College-Al Leith, University of Umm Al-Qura, Makkah 21955, Saudi Arabia.; Khowdiary MM; Department of Chemistry, Faculty of Applied Science, University College-Al Leith, University of Umm Al-Qura, Makkah 21955, Saudi Arabia.

Publisher: Elsevier Country of Publication: United States NLM ID: 8003761 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0909 (Electronic) Linking ISSN: 01410229 NLM ISO Abbreviation: Enzyme Microb Technol Subsets: MEDLINE

Wesson W; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic address: wesson.will@gmail.com.; Dima D; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS; Cleveland Clinic Foundation, Cleveland, OH.; Suleman N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.; Saif MSI; Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS.; Tabak C; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.; Logan E; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.; Davis JA; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC.; McGann M; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC.; Furqan F; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.; Mohan M; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.; Rashid A; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS.; Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS.; Ullah F; Cleveland Clinic Foundation, Cleveland, OH.; Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS.; Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.; Raza S; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS; Cleveland Clinic Foundation, Cleveland, OH.; McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.; Hamadani M; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.; Anwer F; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS; Cleveland Clinic Foundation, Cleveland, OH.; Hashmi H; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS; Department of Medicine, Multiple Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; U.S. Myeloma Innovations Research Collaborative, Kansas City, KS.

Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE

Lin CH; Department of Internal Medicine, Case Western Reserve University, MetroHealth Campus, Cleveland, OH 44109, USA.; Tariq MJ; Department of Hematology-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.; Ullah F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Sannareddy A; Department of Hematology-Oncology, UT Southwestern, Dallas, TX 75235, USA.; Khalid F; Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.; Abbas H; Medical College of Wisconsin, Milwaukee, WI 53226, USA.; Bader A; School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64110, USA.; Samaras C; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Valent J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Anwer F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Raza S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Dima D; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE